NCT00355238 2023-12-01
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
Bristol-Myers Squibb
Phase 2 Completed
Bristol-Myers Squibb
Erasme University Hospital
Dana-Farber Cancer Institute
The University of Hong Kong